Standard Biotools Inc. balance sheet LAB

Annual Quarterly

As of Sep 30, 2026, Standard Biotools Inc. had total assets of $635.3 million and total liabilities of $79.6 million. Total assets were up 17.7% from a year earlier. Stockholders' equity was $555.8 million. It held $559.4 million in cash and investments against $26.5 million of total debt, net cash of $532.8 million. The current ratio, current assets divided by current liabilities, was 9.75.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	267 +106.7%	270 +70.2%	266 +76.1%	121 -27.5%	129 -54.9%	159 -41.2%	151	167 +222.5%
Short-term investments	194 +195.7%	207 +163.4%	189 +76.7%	67 -47.1%	65 -62.6%	78 -37.2%	107	126 +99.6%
Long-term investments	98 +404.2%	67	71	26	19	—	—	—
Cash and investments	559 +160.9%	544 +129.5%	527 +104.0%	213 -27.2%	214 -53.6%	237 -39.9%	258	293 +154.9%
Receivables	13 -4.1%	16 +7.8%	17 -53.1%	13 -8.9%	14 -62.4%	15 -55.0%	35	15 -25.0%
Inventory	18 -30.7%	17 -29.2%	19 -55.9%	20 -3.7%	25 -37.0%	24 -43.3%	42	21 +1.0%
Total current assets	497 +5.3%	517 +2.1%	521 +51.6%	454 +20.9%	472 -13.7%	506 +5.4%	344	376 +137.6%
Property and equipment, net	13 -36.2%	15 -32.5%	17 -60.8%	19 -15.4%	21 -53.7%	23 -46.7%	44	23 -5.8%
Goodwill	—	—	—	—	—	—	112	111 +4.7%
Total assets	635 +17.7%	627 +12.6%	639 +10.3%	568 -7.3%	540 -30.6%	557 -21.4%	580	612 +89.5%
Liabilities and equity
Accounts payable	3 -47.8%	10 +30.4%	8 -32.0%	5 +7.1%	7 -49.6%	7 -41.7%	12	5 -45.3%
Total current liabilities	51 -52.7%	57 -42.1%	42 -25.0%	108 +64.4%	108 -11.2%	98 -20.8%	56	66 -39.7%
Total liabilities	80 -43.1%	87 -34.1%	78 -37.6%	143 +2.0%	140 -30.1%	132 -33.3%	125	141 -12.0%
Stockholders' equity	556 +39.1%	540 +27.2%	561 +23.4%	424 -10.1%	400 -30.8%	425 -16.8%	455	472 +418.6%
Debt
Long-term debt	—	—	—	—	—	—	—	0 -99.5%
Lease liabilities	27 -2.1%	28 -1.9%	29 -6.5%	31 -6.6%	27 -26.7%	28 -20.2%	31	33 -5.8%
Total debt	27 -2.1%	28 -1.9%	29 -6.5%	31 -7.5%	27 -70.5%	28 -68.7%	31	33 -66.4%
Net cash	533 +184.5%	516 +147.3%	497 +119.3%	183 -29.7%	187 -49.4%	209 -31.4%	227	260 +1457.6%
Ratios
Current ratio	9.75x	9.10x	12.36x	4.19x	4.38x	5.16x	6.12x	5.70x
Debt to equity	0.05x	0.05x	0.05x	0.07x	0.07x	0.07x	0.07x	0.07x
Return on equity	23.95%	15.72%	13.94%	-17.65%	-32.09%	-28.38%	—	-29.44%
Return on assets	20.95%	13.54%	12.24%	-13.19%	-23.77%	-21.64%	—	-22.68%
Book value per share	1.41	1.38	1.44	1.10	1.04	1.11	1.20	1.25

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LAB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Boston, MA
SEC filer status: Accelerated filer
SEC CIK: 1162194
Former names: FLUIDIGM CORP (until Apr 1, 2022)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.